MetaCap

Amphastar Pharmaceuticals (AMPH) vs Mineralys Therapeutics (MLYS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amphastar Pharmaceuticals (AMPH) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 8.6% versus a loss of 67.4%. Mineralys Therapeutics is the larger company by market cap ($1.21 billion vs $1.20 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMPH+8.61%MLYS-67.38%
+18%-27%-71%
Nov 21, 20251 yearNov 20, 2026
AMPH-11.08%MLYS-25.92%
+146%+35%-76%
Feb 6, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMPH versus MLYS key metrics
MetricAMPHMLYS
Share price$28.25$13.66
Market cap$1.20B$1.21B
1-day change+0.50%-3.53%
YTD return+5.49%-62.36%
1-year return+8.61%-67.38%
5-year return+41.89%—
P/E ratio (TTM)12.96—
Forward P/E8.43—
EPS (TTM)$2.18$-4.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$719.89M—
Revenue growth (YoY)-1.65%—
Net income (latest FY)$98.09M$-154.65M
Gross margin49.46%—
Operating margin19.50%—
Net margin13.63%—
52-week high$31.00$44.13
52-week low$16.65$13.57
Distance from 52-week high-8.87%-69.05%
Analyst consensusholdstrong_buy
Avg. price target upside-13.27%+218.89%
Average volume475.35K1.55M
Shares outstanding42.65M88.56M
Employees1,97676
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMPH has outperformed MLYS by 76.0 percentage points over the past year.

About Amphastar Pharmaceuticals

AMPH stock →

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees

About Mineralys Therapeutics

MLYS stock →

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

AMPH vs MLYS FAQ

Which is bigger, Amphastar Pharmaceuticals or Mineralys Therapeutics?

Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.21B compared with $1.20B for Amphastar Pharmaceuticals (AMPH).

Which stock has performed better over the past year, AMPH or MLYS?

AMPH returned +8.61% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.

Are Amphastar Pharmaceuticals and Mineralys Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons